Login to Your Account

Pharma: Clinic Roundup

Monday, June 17, 2013

Eli Lilly and Co., of Indianapolis, stopped its Phase II study (BACC) for LY2886721, a beta secretase inhibitor being investigated as a once-daily treatment for its potential to slow the progression of Alzheimer's disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription